 |
第61巻第5号目次 | Japanese/English |
 | Full Text of PDF (168K) Article in Japanese |
─ 原著 ─
Retrospective Treatment Outcomes of Concurrent Chemoradiotherapy in Patients with Stage III Non-small Cell Lung Cancer at a Single Institution: The Pre-PACIFIC Era
Mitsue Kawamura1, Norio Araki1, Noriko Kishi1, Tatsuya Suwa1, Yuki Yamamoto2, Osamu Kanai2, Kohei Fujita2, Misato Okamura2, Koichi Nakatani2, Tadashi Mio21Department of Radiation Oncology, 2Department of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Japan
Objective. To investigate the treatment outcomes in patients with stage III non-small cell lung cancer (NSCLC) after definitive concurrent chemoradiotherapy (CCRT). Methods. We retrospectively reviewed 89 patients who received definitive CCRT for NSCLC in our hospital between April 2008 and March 2018. According to the Union for International Cancer Control system, the clinical stages were IIIA in version 7, IIIB, IIIA in version 8, IIIB, and IIIC in 44, 45, 29, 46, and 14 patients, respectively. Results. The 5-year overall survival (OS) and progression-free survival rates were 48.5％ and 36.1％, respectively. Five-year OS by stage was 57.0％ for stage IIIA in version 7, 41.7％ for stage IIIB (p=0.14), 63.8％ for stage IIIA in version 8, 45.7％ for stage IIIB, and 28.6％ for stage IIIC (p=0.02). Conclusion. CCRT was feasible, safe, and well tolerated in our patients and resulted in survival benefits comparable to those in the published literature. Stage IIIC NSCLC (version 8) was associated with a significantly worse prognosis. Some stage IIIC cases suggested that radiation therapy should not be omitted, even for stage IIIC, and that it is better to increase the intensity of systemic therapy, including durvalumab.
索引用語：Lung cancer, CCRT, 3D-CRT
受付日：October 8, 2020
受理日：June 7, 2021
肺癌 61 (5)：383─388，2021
